Department of Medicine

Department of Medicine

  Division of Hematology/Oncology

[Return To Index page]
photo James J. Lee, MD, PhD

Assistant Professor of Medicine

Division of Hematology-Oncology

Department of Medicine


Phone: 412-648-6586

Office: 5150 Centre Avenue,
Fifth Floor, Room 568
Pittsburgh, PA 15232
Phone: 412-648-6586
Fax: 412-648-6579
Administrative Assistant:
Lois Malehorn
Address: 5150 Centre Avenue
5th floor
Pittsburgh, PA 15232
Phone: 412-648-6589
Education and Training
M.D., Seoul National University, 1988
Ph.D. in Immunology, Johns Hopkins University School of Medicine, 2000
Residency in Medicine, Albert Einstein College of Medicine/Long Island Jewish Medical Center, 2003
Medical Oncology Fellowship, National Cancer Institute/NIH, 2005
Research Interest
The primary focus of my research has been on the design and conduct of early-phase clinical studies of novel agents in colorectal cancer and early drug development in solid tumors. I have designed and conducted several Phase I and Phase II studies in both areas. I have served as a principal investigator of several NCI-sponsored phase I trials at the University of Pittsburgh Cancer Institute and have served as PI for several industry-sponsored phase I/II clinical trials. I am presently a co-investigator of our NCI-UM1 Phase I grant. I have served as the Director of the UPCI Phase I Clinic and the Director of the UPCI Early Phase Clinical Research Support (EPCRS). I have served as a member of the NSABP Foundation Protocol Planning Team for Early Phase Clinical Studies and Colorectal Cancer Committee, and a member of NRG Colorectal Cancer Committee. I have also served on the Colon Cancer Task Force of the NCI Gastrointestinal Steering Committee (GISC). I have two major areas of research interest. 1. Early-phase clinical studies of novel agents in colorectal cancer and early drug development in solid tumors. 2. Development of immunotherapy for the treatment of metastatic colorectal cancer.
Clinical Interest
James J. Lee, MD, PhD, is a medical oncologist who specializes in phase I clinical trials of new cancer drugs and the treatment of gastrointestinal (GI) cancers, especially colon cancer, rectal cancer, and liver cancer. His research has been focused on the development of new cancer drugs including cytotoxic chemotherapeutic agents, biologics, and natural herbal agents. He also has a strong interest in the basic and clinical research of colorectal cancer
Selected Publications:
Lee JJ, Seraj J, Yoshida K, Mizuguchi H, Strychor S, Fiejdasz J, Faulker T, Pollice L, Mason S, Sun W, Chu E, Croft M, Nugteren J, Tedder T, Beumer JH. Human mass balance study of TAS-102 using 14C analyzed by accelerator mass spectrometry. Cancer Chemotherapy and Pharmacology. 2016; 77(3): 515-26.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Wood LD, Cuka N, Pardoll DM,Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM Anders RA, Eshleman JR, Vogelstein B, Diaz LA, Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine. 2015; 372(26): 2509-20.
Lee JJ, Chu E. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Clinical Colorectal Cancer. 2014; 13(3): 135-55.
Lee JJ, Kelly WK. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy. Nature Clinical Practice Oncology. 2009; 6(2): 85-92.
Lee JJ, Swain SM. The epothilones: translating from the laboratory to the clinic. Clinical Cancer Research. 2008; 14(6): 1618-24.
Lee JJ, Chu E. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Clinical Colorectal Cancer. 2007; 6(2): S42-6.
Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. Journal of Clinical Oncology. 2006; 24(10): 1633-42.
Lee JJ, Chu E. An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer Journal. 2007; 13(5): 276-81.
Lee JJ, Low JA, Croarkin E, Parks R, Berman AW, Mannan N, Steinberg SM, Swain SM. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. Journal of Clinical Oncology. 2006; 24(13): 2084-91.
Lee J, Desiderio S. Cyclin A/CDK2 regulates V(D)J recombination by coordinating RAG-2 accumulation and DNA repair. Immunity. 1999; 11(6): 771-81.
Notable Achievements
University of Pittsburgh Cancer Institute Junior Scholar Award, 2014
Member, Colon Cancer Task Force of NCI Gastrointetinal Steering Committee, 2016-present
Member, Editorial Board, Clinical Colorectal Cancer, 2006-present
Member, Editorial Board, Oncology Research, 2015-present
Member, Editorial Board, Advanceds in Gastrointestinal Cancer, 2015-present